Article
The Alzheimer’s therapeutic Lecanemab induces an amyloid-clearing program in microglia
2025-07-27
Abstract excerpt
Controversies over anti-amyloid immunotherapies underscore the need to elucidate their mechanisms of action. Here we demonstrate that Lecanemab, a leading anti-Aβ antibody, mediates amyloid clearance by triggering effector functions in the microglia. Using a human microglia xenograft model, we show that Lecanemab significantly reduces Aβ pathology and associated neuritic damage, while neither Fc-inactivated Lecane...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- cc8616ac-d240-5c2d-8c0e-674d28a7f0af
- DOI
- 10.1101/2025.07.24.666347
